Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma after Donor-Derived CD7- Chimeric Antigen Receptor T-Cell Therapy

Background: In our phase I clinical trial, 90% complete remission (CR) in r/r T-ALL/LBL has been achieved with donor-derived CD7-chimeric antigen receptor T-cell (CART) therapy (Pan J. et al. JCO July 29, 2021 online), but hematopoiesis and immune reconstitution is crucial for long-term disease-free survival (DFS) in this setting.